Eli Lilly launches program to boost employer coverage of obesity drugs
Eli Lilly on Thursday launched a new program designed to help more employers cover obesity drugs in the…
Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly
Novo Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its…
What’s next for Novo Nordisk’s obesity drug CagriSema
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news…
The market is so on edge about AI that it’s selling off Monday on an unlikely source
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
Eli Lilly launches Zepbound obesity drug pen with one month of doses
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March…
Eli Lilly (LLY) earnings Q4 2025
Eli Lilly on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand…
Pfizer’s monthly obesity injection drove shows promise in trial
Smith Collection | Archive Photos | Getty Images Pfizer on Thursday said its experimental obesity drug, which it…
Eli Lilly CEO David Ricks talks Medicare coverage of obesity pills
Eli Lilly CEO Dave Ricks on Friday said upcoming Medicare coverage of obesity drugs could be a major…
Eli Lilly plans $3.5 billion Pennsylvania plant for obesity drugs
Eli Lilly Chair and CEO Dave Ricks speaks during a press conference in Houston, Sept. 23, 2025. Antranik…
Next steps for Eli Lilly, Novo Nordisk, Pfizer
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George…
Another alliance of health care and AI signals why pharma stocks could be back
Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the…
Novo Nordisk shares rise after Wegovy obesity pill launch
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, US, on Thursday, Jan.…